---
document_datetime: 2025-11-23 08:05:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/viraferonpeg.html
document_name: viraferonpeg.html
version: success
processing_time: 0.1202664
conversion_datetime: 2025-12-28 04:19:55.315337
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# ViraferonPeg

[RSS](/en/individual-human-medicine.xml/65820)

##### Withdrawn

This medicine's authorisation has been withdrawn

peginterferon alfa-2b

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on ViraferonPeg](#news-on)
- [More information on ViraferonPeg](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 11 January 2021, the European Commission withdrew the marketing authorisation for ViraferonPeg (peginterferon alfa-2b) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp &amp; Dohme B.V, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

ViraferonPeg was granted marketing authorisation in the EU on 29 May 2000 for the treatment of hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2005. It was then granted unlimited validity in 2010.

The European Public Assessment Report (EPAR) for ViraferonPeg is updated to indicate that the marketing authorisation is no longer valid.

ViraferonPeg : EPAR - Summary for the public

English (EN) (645.81 KB - PDF)

**First published:** 04/03/2008

**Last updated:** 22/01/2021

[View](/en/documents/overview/viraferonpeg-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-476)

български (BG) (854.28 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/bg/documents/overview/viraferonpeg-epar-summary-public_bg.pdf)

español (ES) (639.5 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/es/documents/overview/viraferonpeg-epar-summary-public_es.pdf)

čeština (CS) (745.07 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/cs/documents/overview/viraferonpeg-epar-summary-public_cs.pdf)

dansk (DA) (645.15 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/da/documents/overview/viraferonpeg-epar-summary-public_da.pdf)

Deutsch (DE) (647.52 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/de/documents/overview/viraferonpeg-epar-summary-public_de.pdf)

eesti keel (ET) (702.66 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/et/documents/overview/viraferonpeg-epar-summary-public_et.pdf)

ελληνικά (EL) (805.92 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/el/documents/overview/viraferonpeg-epar-summary-public_el.pdf)

français (FR) (709.77 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/fr/documents/overview/viraferonpeg-epar-summary-public_fr.pdf)

italiano (IT) (651.4 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/it/documents/overview/viraferonpeg-epar-summary-public_it.pdf)

latviešu valoda (LV) (765.99 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/lv/documents/overview/viraferonpeg-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (739.6 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/lt/documents/overview/viraferonpeg-epar-summary-public_lt.pdf)

magyar (HU) (735.92 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/hu/documents/overview/viraferonpeg-epar-summary-public_hu.pdf)

Malti (MT) (744.47 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/mt/documents/overview/viraferonpeg-epar-summary-public_mt.pdf)

Nederlands (NL) (725.37 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/nl/documents/overview/viraferonpeg-epar-summary-public_nl.pdf)

polski (PL) (806.88 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/pl/documents/overview/viraferonpeg-epar-summary-public_pl.pdf)

português (PT) (704.64 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/pt/documents/overview/viraferonpeg-epar-summary-public_pt.pdf)

română (RO) (682.31 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/ro/documents/overview/viraferonpeg-epar-summary-public_ro.pdf)

slovenčina (SK) (739.94 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/sk/documents/overview/viraferonpeg-epar-summary-public_sk.pdf)

slovenščina (SL) (796.46 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/sl/documents/overview/viraferonpeg-epar-summary-public_sl.pdf)

Suomi (FI) (708.53 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/fi/documents/overview/viraferonpeg-epar-summary-public_fi.pdf)

svenska (SV) (644.71 KB - PDF)

**First published:**

04/03/2008

**Last updated:**

22/01/2021

[View](/sv/documents/overview/viraferonpeg-epar-summary-public_sv.pdf)

## Product information

ViraferonPeg : EPAR - Product Information

English (EN) (5.43 MB - PDF)

**First published:** 17/09/2009

**Last updated:** 22/01/2021

[View](/en/documents/product-information/viraferonpeg-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-566)

български (BG) (9.48 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/bg/documents/product-information/viraferonpeg-epar-product-information_bg.pdf)

español (ES) (4.48 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/es/documents/product-information/viraferonpeg-epar-product-information_es.pdf)

čeština (CS) (8.03 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/cs/documents/product-information/viraferonpeg-epar-product-information_cs.pdf)

dansk (DA) (7.89 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/da/documents/product-information/viraferonpeg-epar-product-information_da.pdf)

Deutsch (DE) (5.2 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/de/documents/product-information/viraferonpeg-epar-product-information_de.pdf)

eesti keel (ET) (5.55 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/et/documents/product-information/viraferonpeg-epar-product-information_et.pdf)

ελληνικά (EL) (9.75 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/el/documents/product-information/viraferonpeg-epar-product-information_el.pdf)

français (FR) (6.17 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/fr/documents/product-information/viraferonpeg-epar-product-information_fr.pdf)

hrvatski (HR) (5.72 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/hr/documents/product-information/viraferonpeg-epar-product-information_hr.pdf)

íslenska (IS) (5.64 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/is/documents/product-information/viraferonpeg-epar-product-information_is.pdf)

italiano (IT) (4.38 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/it/documents/product-information/viraferonpeg-epar-product-information_it.pdf)

latviešu valoda (LV) (8.16 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/lv/documents/product-information/viraferonpeg-epar-product-information_lv.pdf)

lietuvių kalba (LT) (10.28 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/lt/documents/product-information/viraferonpeg-epar-product-information_lt.pdf)

magyar (HU) (6.62 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/hu/documents/product-information/viraferonpeg-epar-product-information_hu.pdf)

Malti (MT) (8.83 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/mt/documents/product-information/viraferonpeg-epar-product-information_mt.pdf)

Nederlands (NL) (6.73 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/nl/documents/product-information/viraferonpeg-epar-product-information_nl.pdf)

norsk (NO) (5.66 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/no/documents/product-information/viraferonpeg-epar-product-information_no.pdf)

polski (PL) (4.4 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/pl/documents/product-information/viraferonpeg-epar-product-information_pl.pdf)

português (PT) (5.89 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/pt/documents/product-information/viraferonpeg-epar-product-information_pt.pdf)

română (RO) (5.89 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/ro/documents/product-information/viraferonpeg-epar-product-information_ro.pdf)

slovenčina (SK) (8.03 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/sk/documents/product-information/viraferonpeg-epar-product-information_sk.pdf)

slovenščina (SL) (6.43 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/sl/documents/product-information/viraferonpeg-epar-product-information_sl.pdf)

Suomi (FI) (4.57 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/fi/documents/product-information/viraferonpeg-epar-product-information_fi.pdf)

svenska (SV) (4.29 MB - PDF)

**First published:**

17/09/2009

**Last updated:**

22/01/2021

[View](/sv/documents/product-information/viraferonpeg-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0128 27/09/2018

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

ViraferonPeg : EPAR - All Authorised presentations

English (EN) (655.47 KB - PDF)

**First published:** 11/08/2006

**Last updated:** 22/01/2021

[View](/en/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-492)

български (BG) (835.14 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/bg/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_bg.pdf)

español (ES) (662.48 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/es/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_es.pdf)

čeština (CS) (838.22 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/cs/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (680.43 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/da/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (710.6 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/de/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (665.26 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/et/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (815.8 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/el/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_el.pdf)

français (FR) (669.11 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/fr/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (675.37 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/hr/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (655.87 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/is/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_is.pdf)

italiano (IT) (659.2 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/it/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (817.41 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/lv/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (691.22 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/lt/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (766.49 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/hu/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (774.93 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/mt/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (674.75 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/nl/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (673.56 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/no/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_no.pdf)

polski (PL) (816.67 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/pl/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_pl.pdf)

português (PT) (660.05 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/pt/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_pt.pdf)

română (RO) (691.98 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/ro/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (798.92 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/sk/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (787.39 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/sl/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (706.2 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/fi/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (673.04 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

22/01/2021

[View](/sv/documents/all-authorised-presentations/viraferonpeg-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine ViraferonPeg Active substance peginterferon alfa-2b International non-proprietary name (INN) or common name peginterferon alfa-2b Therapeutic area (MeSH) Hepatitis C, Chronic Anatomical therapeutic chemical (ATC) code L03AB10

### Pharmacotherapeutic group

Immunostimulants

### Therapeutic indication

**Adults (tritherapy)**

ViraferonPeg in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic-hepatitis-C (CHC) genotype-1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy.

Please refer to the ribavirin and boceprevir summaries of product characteristics (SmPCs) when ViraferonPeg is to be used in combination with these medicines.

**Adults (bitherapy and monotherapy)**

ViraferonPeg is indicated for the treatment of adult patients (18 years of age and older) with CHC who are positive for hepatitis-C-virus RNA (HCV-RNA), including patients with compensated cirrhosis and / or co-infected with clinically stable HIV.

ViraferonPeg in combination with ribavirin (bitherapy) is indicated for the treatment of CHC infection in adult patients who are previously untreated including patients with clinically stable HIV co-infection and in adult patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated) and ribavirin combination therapy or interferon alpha monotherapy.

Interferon monotherapy, including ViraferonPeg, is indicated mainly in case of intolerance or contraindication to ribavirin.

Please refer to the ribavirin SmPC when ViraferonPeg is to be used in combination with ribavirin.

**Paediatric population (bitherapy)**

ViraferonPeg is indicated in a combination regimen with ribavirin for the treatment of children three years of age and older and adolescents, who have chronic hepatitis C, previously untreated, without liver decompensation, and who are positive for HCV-RNA.

When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The decision to treat should be made on a case-by-case basis.

Please refer to the ribavirin SmPC for capsules or oral solution when ViraferonPeg is to be used in combination with ribavirin.

## Authorisation details

EMA product number EMEA/H/C/000329 Marketing authorisation holder

Merck Sharp  Dohme Ltd

Merck Sharp  Dohme Ltd

Opinion adopted 17/02/2000 Marketing authorisation issued 28/05/2000 Withdrawal of marketing authorisation 11/01/2021 Revision 36

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

ViraferonPeg : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.18 MB - PDF)

**First published:** 17/09/2009

**Last updated:** 22/01/2021

[View](/en/documents/procedural-steps-after/viraferonpeg-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

ViraferonPeg-H-C-329-PSUV-0110: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/322798/2014

English (EN) (636.04 KB - PDF)

**First published:** 11/06/2014

**Last updated:** 22/01/2021

[View](/en/documents/scientific-conclusion/viraferonpeg-h-c-329-psuv-0110-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

ViraferonPeg-H-C-329-WS-0216 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/393220/2012

English (EN) (2.53 MB - PDF)

**First published:** 04/09/2012

**Last updated:** 22/01/2021

[View](/en/documents/variation-report/viraferonpeg-h-c-329-ws-0216-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for ViraferonPeg

Adopted

Reference Number: EMA/CHMP/114049/2012

English (EN) (688.29 KB - PDF)

**First published:** 17/02/2012

**Last updated:** 22/01/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-viraferonpeg_en.pdf)

ViraferonPeg-H-C-329-II-0084 : EPAR - Assessment Report - Variation

Adopted

English (EN) (950.51 KB - PDF)

**First published:** 22/01/2010

**Last updated:** 22/01/2010

[View](/en/documents/variation-report/viraferonpeg-h-c-329-ii-0084-epar-assessment-report-variation_en.pdf)

ViraferonPeg-H-C-329-II-0086 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/6059/2010

English (EN) (926.26 KB - PDF)

**First published:** 22/01/2010

**Last updated:** 22/01/2021

[View](/en/documents/variation-report/viraferonpeg-h-c-329-ii-0086-epar-assessment-report-variation_en.pdf)

CHMP post authorisation summary of positive opinion for ViraferonPeg on 24 September 2009

Adopted

Reference Number: EMEA/CHMP/612232/2009

English (EN) (607.43 KB - PDF)

**First published:** 24/09/2009

**Last updated:** 22/01/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-viraferonpeg-24-september-2009_en.pdf)

ViraferonPeg-H-C-329-II-0068 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (903.25 KB - PDF)

**First published:** 03/12/2007

**Last updated:** 22/01/2021

[View](/en/documents/scientific-discussion-variation/viraferonpeg-h-c-329-ii-0068-epar-scientific-discussion-variation_en.pdf)

ViraferonPeg-H-C-329-II-0067 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (806.08 KB - PDF)

**First published:** 02/08/2007

**Last updated:** 22/01/2021

[View](/en/documents/scientific-discussion-variation/viraferonpeg-h-c-329-ii-0067-epar-scientific-discussion-variation_en.pdf)

ViraferonPeg : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (673.57 KB - PDF)

**First published:** 11/08/2006

**Last updated:** 22/01/2021

[View](/en/documents/steps-after-cutoff/viraferonpeg-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

ViraferonPeg-H-C-329-II-0053 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (751.94 KB - PDF)

**First published:** 11/08/2006

**Last updated:** 22/01/2021

[View](/en/documents/scientific-discussion-variation/viraferonpeg-h-c-329-ii-0053-epar-scientific-discussion-variation_en.pdf)

ViraferonPeg-H-C-329-II-0045 : EPAR - Scientific Discussion - Variation

Adopted

Reference Number: EMEA/H/C/329/II/45

English (EN) (749.16 KB - PDF)

**First published:** 11/08/2006

**Last updated:** 22/01/2021

[View](/en/documents/scientific-discussion-variation/viraferonpeg-h-c-329-ii-0045-epar-scientific-discussion-variation_en.pdf)

## Initial marketing authorisation documents

ViraferonPeg : EPAR - Procedural steps taken before authorisation

English (EN) (665.3 KB - PDF)

**First published:** 11/08/2006

**Last updated:** 22/01/2021

[View](/en/documents/procedural-steps/viraferonpeg-epar-procedural-steps-taken-authorisation_en.pdf)

ViraferonPeg : EPAR - Scientific Discussion

English (EN) (967.54 KB - PDF)

**First published:** 11/08/2006

**Last updated:** 22/01/2021

[View](/en/documents/scientific-discussion/viraferonpeg-epar-scientific-discussion_en.pdf)

#### News on ViraferonPeg

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-february-2012) 17/02/2012

#### More information on ViraferonPeg

- [EMEA-000384-PIP01-08 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000384-pip01-08)

**This page was last updated on** 22/01/2021

## Share this page

[Back to top](#main-content)